Prevention and Treatment of Cardiac Rhythm Disorders in Pregnant Women with Arterial Hypertension

Authors

  • Makhmudjonova Sh.M. . Author
  • Makhmudjonova Sh.M. . Author
  • Rakhmonov K.Kh., . Author

Keywords:

Keywords: cardiac rhythm disorders, pregnancy, beta-blocker, methyldopa, Holter monitoring

Abstract

To prevent and assess cardiac rhythm disorders (CRDs) and conduction disorders in pregnant women with gestational and chronic arterial  hypertension .

References

1.Conti, E., Cascio, N. D., Paluan, P., Racca, G., Longhitano, Y., Savioli, G., Tesauro, M., Leo, R., Racca, F., & Zanza, C. (2024). Pregnancy Arrhythmias: Management in the Emergency Department and Critical Care. Journal of clinical medicine, 13(4), 1095. https://doi.org/10.3390/jcm13041095

2.2025 ESC Guidelines for the management of cardiovascular disease and pregnancy: Developed by the task force on the management of cardiovascular disease and pregnancy of the European Society of Cardiology (ESC)

Endorsed by the European Society of Gynecology (ESG) https://doi.org/10.1093/eurheartj/ehaf193

3.Tamirisa, K. P., Elkayam, U., Briller, J. E., Mason, P. K., Pillarisetti, J., Merchant, F. M., Patel, H., Lakkireddy, D. R., Russo, A. M., Volgman, A. S., & Vaseghi, M. (2022). Arrhythmias in Pregnancy. JACC. Clinical electrophysiology, 8(1), 120–135. https://doi.org/10.1016/j.jacep.2021.10.004

4.Fischer AJ, Diller GP, Uebing A, Nürnberg JH, Hebe J. Antiarrhythmic drugs-safety and efficacy during pregnancy. Herzschrittmacherther Elektrophysiol. 2021 Jun;32(2):145-151. English. doi: 10.1007/s00399-021-00759-2. Epub 2021 Mar 29. PMID: 33779803. https://pubmed.ncbi.nlm.nih.gov/33779803

5.Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf. 1999 Jan;20(1):85-94. doi: 10.2165/00002018-1999Mariani MV, Pierucci N, La Fazia VM, Cipollone P, Micillo M, D'Amato A, Fanisio F, Ammirati G, Salagundla N, Lavalle C, Perrone MA. Antiarrhythmic Drug Use in Pregnancy: Considerations and Safety Profiles. J Cardiovasc Dev Dis. 2024 Aug 7;11(8):243. doi: 10.3390/jcdd11080243. PMID: 39195151; PMCID: PMC11354975.20010-00008. PMID: 9935279. https://pubmed.ncbi.nlm.nih.gov/9935279

6.Hudson RE, Metz TD, Ward RM, McKnite AM, Enioutina EY, Sherwin CM, Watt KM, Job KM. Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure. Front Pharmacol. 2023 Mar 23;14:1111601. doi: 10.3389/fphar.2023.1111601. PMID: 37033628; PMCID: PMC10076747. https://pmc.ncbi.nlm.nih.gov/articles/PMC10076747

7.Mariani MV, Pierucci N, La Fazia VM, Cipollone P, Micillo M, D'Amato A, Fanisio F, Ammirati G, Salagundla N, Lavalle C, Perrone MA. Antiarrhythmic Drug Use in Pregnancy: Considerations and Safety Profiles. J Cardiovasc Dev Dis. 2024 Aug 7;11(8):243. doi: 10.3390/jcdd11080243. PMID: 39195151; PMCID: PMC11354975. https://pubmed.ncbi.nlm.nih.gov/39195151

Downloads

Published

2026-10-19